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ABSTRACT
Objectives: The objective of this study was to determine the maternal PLAC1 protein levels in early and late onset preec-
lampsia. 
Material and methods: A total of 135 pregnant women were included in the study, of which 55 were at < 34 weeks of gesta-
tion and 80 were at ≥ 34 weeks of gestation, between June and November 2014 were recruited in this case control study. 
Results: Analysis of maternal serum PLAC1 levels did not reveal any significant differences between early onset PE and 
controls (p = 0.422). However, late onset PE patients exhibited significantly elevated levels of PLAC1, in comparison with 
healthy controls (p = 0.026). The difference in PLAC1 levels between early onset PE and late onset PE was also significant 
(p = 0.001). Area under ROC curve of PLAC1 for early and late onset PE was 0.563 and 0.646 with p values of 0.422 and 
0.026 respectively. Area under ROC curve of PLAC1 in PE was 0.613 with p value = 0.024. The cutoff value for PLAC1 was 
6.19 ng/mL with sensitivity: 56% (95% CI 44.1–67.3) and specificity: 63 %; (95% CI 49.9–75.1) and diagnostic odds ratio: 
2.2 (95% CI 1.1–4.4) (p value = 0.037). The cutoff value for PLAC1 was 7.2 ng/mL with sensitivity: 43% (95% CI 31.5–54.6) 
and specificity: 78% (95% CI 65.5–87.5) and diagnostic odds ratio: 2.69 (95% CI 1.25–5.79) (p value = 0.016) 
Conclusion: In conclusion, the results of the current study showed that PLAC1 protein levels were significantly elevated 
in pregnant women with late onset PE in comparison with healthy control group.
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INTRODUCTION
Preeclampsia (PE) is a multi-system disorder and a major 
cause of maternal and fetal mortality or serious morbidity. 
However, most affected pregnancies end up at term with 
good maternal and fetal outcomes [1, 2]. Gestational hy-
pertensive disorders cause complications in approximately 
5–10% of all pregnancies [3]. According to WHO2014 data, 
the second most common cause for maternal mortality 
is pregnancy-related hypertensive disorders (14%) after 
hemorrhage [4]. In most women, the clinical features first 
come into view after 34 weeks of gestation (late onset PE). 
However, 10% of women develop PE before the 34th week 
of gestation (early onset PE) [5]. 2003 and 2008 studies of 
PE indicate that differences in its origins seem to result in 
phenotypic alterations of subtypes [5, 6]. Jackman SM, et al 
report that some proteins are involved in specific protein 
interactions with reference to a role at the maternal-fetal in-
terface and are essential for normal placental development 
[7]. In Chang WL, et al there is evidence that suggests that 
Human placenta-specific protein-l (PLACI) is an important 
protein in placental development [8]. Jackman SM, et al also 
show that deficiency of placental PLAC1 protein results in 
hyperplastic placenta, and dysmorphic junctional zone [7].
The aim of our study was to determine the maternal 
PLAC1 protein levels in early- and late-onset PE pregnancies 
as there is potential for the protein levels to play a role in 
placental dysfunction.
MATERIAL AND METHODS
The protocol of this study was approved by the Ethics 
Committee of the Planning and Coordination Center at 
Dr. Zekai Tahir Burak Women’s Health Care, Education and 
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Research Hospital (#18/2014) and informed consent was 
obtained from all participants before enrollment. The study 
followed the tenets of the Declaration of Helsinki [9].
Between June and November 2014, 135 pregnant wo-
men who had been admitted to the perinatology depart-
ment of a tertiary referral hospital were enrolled in the 
study. PE was defined as elevated blood pressure in a pre-
viously normotensive woman after 20 weeks of gestation, 
either ≥ 140/90 mmHg on two occasions at least four hours 
apart or ≥ 160/110 mmHg within a short interval (minutes 
apart); and a proteinuria of ≥ 300 mg in a 24-hour urine 
specimen [1]. In the absence of proteinuria, the diagnostic 
criteria consisted of new-onset hypertension together with 
thrombocytopenia, renal failure, poor liver function, pulmo-
nary edema, or any visual symptoms [1]. Pregnancies with 
PE before 34 weeks of gestation were defined as early-onset 
preeclampsia, whereas pregnancies after 34 weeks were 
specified as late-onset PE. The control group was comprised 
of pregnant women with unremarkable pregnancy follow-
-ups. The exclusion criteria for the study and control groups 
were the presence of multiple pregnancies, systemic disease, 
a history of alcohol use or smoking and any chronic drug use.
On, admission, venous blood samples (10 cc) were col-
lected in tubes containing ethylenediaminetetraacetic acid. 
The samples were centrifuged for 10 min and the plasmas 
were stored at –80°C for subsequent assay. The maternal 
serum PLAC1 protein levels were determined using a san-
dwich enzyme-based technique in accordance with the 
manufacturer’s instructions. (Cusabio Biotech Co., Stratech 
Scientific Limited. United Kingdom). Results were expressed 
as ng/mL.
The Statistical Package for Social Sciences (SPSS) for Win-
dows 23.0 (SPSS Inc., Chicago, IL) was used for the analysis of 
the data. The normality of the variables was assessed by the 
Shapiro-Wilk test. Differences between the two independent 
groups were compared by Student’s t and Mann-Whitney 
U tests, where appropriate. The detection and false-positive 
rates of PLAC1 for the prediction of PE were estimated by 
using Receiver Operating Characteristic (ROC) curves ana-
lysis. A two-tailed p value of less than 0.05 was considered 
to be statistically significant. Calculations for sensitivity, 
specificity, positive predictive value (PPV), negative predic-
tive value (NPV), and positive likelihood ratio were carried 
out. Also checked were the negative likelihood ratio and 
diagnostic odds ratio with their associated 95% CI.
RESULTS
Of the total of 135 pregnant women included in the 
study, 55 were at the < 34-week gestation and 80 were 
at ≥ 34-week gestation.
Table 1 illustrates the clinical picture of the patients 
at ≥ 34 weeks of gestation. There were 30 patients with early 
onset PE and 25 in the control group. No significant diffe-
rences were observed between the study group and control 
group in terms of their age, body mass index, gravida, ge-
stational age, fetal biometric measurements, liver enzyme 
Table 1. The clinical characteristics of the study participants at < 34 weeks of gestation
Early onset Preeclampsia (n = 30) Control (n = 25) p
Age (years) 30.0 ± 4.5 29.7 ± 6.0 0.813
Body mass index [kg/m2] 30 ± 5 28 ± 4 0.163
Gravida (number) 2 ± 1 2 ± 1 0.145
Gestational age (weeks) 31.0 ± 2.3 31.1 ± 2.2 0.833
Systolic blood pressure [mmHg] 153.00 ± 12.08 113.60 ± 6.38 < 0.001
Diastolic blood pressure [mmHg] 106.33 ± 7.18 68.80 ± 7.81 < 0.001
Birthweight [grams] 1956.0 ± 837.1 2682.0 ± 768.3 0.002
BPD (weeks) 30.90 ± 2.55 30.48 ± 2.40 0.475
AC (weeks) 30.57 ± 2.57 30.44 ± 2.38 0.738
FL (weeks) 30.40 ± 2.63 30.44 ± 2.50 0.966
24 hour urine protein [milligrams] 828.17 ± 460.30 — < 0.001
Thrombocytes [/µl] 228733.3 ± 81062.7 251240.0 ± 66979.6 0.299
Alanine transaminase [IU/L] 23.33 ± 12.08 19.00 ± 5.42 0.162
Aspartate transaminase [IU/L] 16.23 ± 10.94 13.08 ± 6.87 0.165
Urea [mg/dL] 20.57 ± 7.73 15.16 ± 5.58 0.003
Creatinine [mg/dL] 0.73 ± 0.10 0.62 ± 0.11 < 0.001
APGAR score at 5 minute 7.90 ± 2.23 9.04 ± 1.37 0.024
p < 0.05 indicates significant difference. Data are expressed as mean ± standard deviation
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serum levels, and thrombocyte count (p > 0.05). With the 
exception of lower neonatal birth weight and a low Apgar 
score at minute 5 (p < 0.05), all of the preeclamptic group, 
namely systolic and diastolic blood pressure, serum urea 
and creatinine, and 24-hour urine protein, were elevated.
Table 2 illustrates the clinical picture of the pregnant 
women at the ≥ 34th week of gestation. There were 45 pa-
tients with late onset PE and 35 in the control group. In 
patients with late onset PE, higher gravidity, higher systolic 
and diastolic blood pressure, elevated serum urea and cre-
atinine values, 24-hour urine protein, lower femur length 
measurement and a low Apgar score at minute 5 were de-
tected (p < 0.05). No statistically significant differences were 
found between the study and control groups with regard 
to their age, body mass index, gestational age, abdominal 
circumference and bi-parietal diameter measurements, neo-
natal birth-weight, liver enzymes and thrombocyte levels 
(p > 0.05).
Analysis of maternal serum PLAC1 levels did not reveal 
any significant differences between early onset PE and the 
control group (5.49 ± 12.24 g/mL vs. 4.96 ± 1.79 ng/mL, 
p = 0.422). However, the late onset PE patients exhibited 
significantly elevated levels of PIACI, in comparison with the 
healthy control group (8.25 ± 3.52 ng/ml vs. 6.83 ± 4.19 ng/mL, 
P = 0.026). The difference in PLAC1 levels between early onset 
PE and late onset PE was also significant (5.49 + 2.24 ng/mL 
vs. 8.25 ± 3.52 ng/mL, p = 0.001) (Tab. 3). No association was 
found between the severity of the disease and PLAC1 levels 
in either the early-onset PE or late-onset PE groups (Tab. 4).
The area under the ROC curve of the PLAC1 for early- 
and late-onset PE was 0.563 and 0.646 with p values of 
0.422 and 0.026 respectively. The area under the ROC curve 
of the PLAC1 in PE was 0.613 with p value = 0.024. The cut-
-off value for PLAC1 was 6.19 ng/mL with sensitivity of 56% 
(95% CI 44.1–67.3), specificity of 63%; (95% CI 49.9–75.1), 
and a diagnostic odds ratio of 2.2 (95% CI 1.1–4.4) (p va-
lue — 0.037). The cut-off value for PLAC1 was 7.2 ng/mL 
with sensitivity: 43% (95% CI 31.5-54.6) and specificity: 78% 
(95% CI 65.5–87.5) and a diagnostic odds ratio: 2.69 (95% CI 
1.25–5.79) (p value = 0.016) (Tab. 5).
Table 2. The clinical characteristics of the study participants at ≥ 34 weeks of gestation
  Late onset Preeclampsia (n = 45) Control (n = 35) p
Age (years) 31.1 ± 5.9 28.2 ± 5.5 0.031
Body mass index [kg/m2] 32 ± 5 31 ± 4 0.510
Gravida (number) 3 ± 2 2 ± 1 0.034
Gestational age (weeks) 37.4 ± 1.5 38.1 ± 2.0 0.218
Systolic blood pressure [mmHg] 150.60 ± 12.78 114.57 ± 8.17 < 0.001
Diastolic blood pressure [mmHg] 103.71 ± 11.33 72.91 ± 982 < 0.001
Birthweight [grams] 3154.7 ± 623.9 3202.9 ± 442.9 0.957
BPD (weeks) 37 ± 2 37 ± 1 0.524
AC (weeks) 37 ± 2 37 ± 2 0.941
FL (weeks) 36 ± 1 37 ± 1 0.031
24 hour urine protein [milligrams] 773.04 ± 963.13 N/A < 0.001
Thrombocytes [/µl] 235.000 ± 61.000 254.000 ± 69.000 0.455
Alanine transaminase [IU/L] 24 ± 34 19 ± 5 0.846
Aspartate transaminase [IU/L] 24 ± 71 12 ± 5 0.630
Urea [mg/dL] 20 ± 6 15 ± 4 < 0.001
Creatinine [mg/dL] 0.71 ± 0.11 0.62 ± 0.08 < 0.001
APGAR score at 5 minute 8.93 ± 1.10 9.49 ± 0.56 0.001
Table 3. Comparison of PLAC 1 levels
Maternal serum PLAC1 [ng/mL]
Gestational age < 34 weeks Gestational age ≥ 34 weeks p
Control 4.96 ± 1.79 6.83 ± 4.19
Preeclampsia 5.49 ± 2.24 8.25 ± 3.52 0.001a
P 0.422 0.026
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DISCUSSION
The present study showed an increase in maternal serum 
PLAC1 protein levels in late onset PE compared with the con-
trol and the early-onset PE groups. However, no association 
was established between the severity of PE and PLAC1 levels 
in either the early- or late-onset groups.
Though many theories have been proposed, the etiology 
of PE remains unknown. Impaired placentation, oxidative 
stress, thrombocyte and thrombin activation are among the 
pathogenetic mechanisms of PE together with endothelial 
dysfunction, imbalance of angiogenesis and intravascular 
inflammation [10]. Valensise et al. and von Dadelszen et al. 
reported that the variety in the pathophysiology of these 
disorders results in the different presentations of the disease 
(early- and late-onset PE) [5, 6]. Vatten et al. reported that 
placental dysfunction constitutes the basis of early-onset PE, 
whereas the composition of other factors may play a role in 
the development of the late-onset of the disorder [11]. Fant 
et al. found that apoptotic changes within placental villus 
trophoblast and leakage from the damaged placental villus 
trophoblast due to hypoxia or oxidative stress were the causes 
of the increase in plasma proteins in preeclamptic women [12].
Cocchia et al. recently identified a placenta-specific gene 
on the Xq26 chromosome as the PLAC1 gene and it has 
been shown that the gene expression is observed from the 
beginning of pregnancy until the end in the human pla-
centa [13, 14]. The PLAC1 gene may facilitate trophoblastic 
interactions peculiar to the placental-uterine interface [13] 
and may constitute a marker of placental development [15]. 
PLAC1 mRNA expression is restricted to cells of trophoblastic 
lineage [13, 14, 16]. Detectable expressions of PLAC1 mRNA 
are not observed in adult or fetal tissues. However, recent 
studies demonstrated decreased levels in testis and cerebel-
lum [17]. PLAC1 is localized in human placental syncytiotro-
phoblast [16, 18]. These observations are indications of the 
PLAC1 polypeptide being a membrane-associated protein. 
Whether PLAC1 is localized extracellularly, intracellularly, or 
is, in fact, an integral membrane component that becomes 
internalized is still not clear from these studies. Human am-
niotic fluid (16–18-week gestation) and maternal serum 
(25–33 weeks) analysis show no identification of the soluble 
PLAC1 protein in these compartments. This suggests that 
the PLAC1 polypeptide does not circulate. However, it acts 
locally at the level of the trophoblast [12].
The restricted nature of PLAC1 expression suggests 
it might serve as a useful biomarker that is indicative of 
functional disruptions at the maternal-fetal interface. This 
explanation was supported by Concu et al. [15] in their study 
which demonstrated that PLAC1 mRNA can be found in ma-
ternal serum as early as the 8th week of gestation and during 
pregnancy. The half-life of circulating fetal DNA increases 
fourfold in patients with preeclampsia [19]. The occurrence 
of higher circulating concentrations of the PLAC1 protein, 
observed in preeclampsia, might be contributed by similar 
mechanisms. Kodama et al. demonstrated that cell-free 
mRNA levels of PLAC1 were eight times higher in preec-
lamptic patients compared with their control group [20]. 
In previous studies, PLAC1 gene expression was reported 
as higher in PE patients compared with results for control 
groups [21, 22]. Farina et al. showed that there is a decre-
Table 5. Diagnostic performances of PLAC1 
PLAC1
CUT-OFF 6.19
PLAC1
CUT-OFF 7.2
Sensitivity (%) and 95% CI 56 (44.1–67.28) 42.67 (31.48–54.6)
Specificity (%) and 95% CI 63.33 (49.85–75.11) 78.33 (65.46–87.52)
Positive Likelihood Ratio and 95% CI 1.53 (1.04–2.25) 1.97 (1.14–3.41)
Negative Likelihood Ratio and 95% CI 0.70 (0.53–0.91) 0.73 (0.60–0.90)
Positive Predictive Value (%) and 95% CI 65.63 (52.61–76.75) 71.11 (55.48–83.16)
Negative Predictive Value (%) and 95% CI 53.52 (41.36–65.3) 52.22 (41.49–62.77)
Diagnostic Odds Ratio and 95% CI 2.2 (1.1–4.4) 2.69 (1.25 5.79)
Table 4. Impact of factors on PLAC1 levels
PLAC 1
Early onset PE Late onset PE
n Mean ± SD p* n Mean ± SD p*
Severity of disease
MILD 10 5.36 ± 2.06
0,948
20 8.17 ± 3.85
0.689
SEVERE 20 5.55 ± 2.38 25 8.32 ± 3.41
SD — Standart deviation; * — Mann-Whitney U Test
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ased level of circulating PLAC1 mRNA in cases associated 
with the risk of abortion before the 20th week of gestation. 
This, however, is not applicable for pregnancies after the 
20th week [23]. Subsequent studies reported high levels 
of circulating PLAC1 mRNA in preeclampsia. These were in 
direct relation to the severity of the disease [22]. Ng et al. 
suggested different ways to clarify the fluctuations in circu-
lating PLAC1 mRNA with PE [24]. The first elevated apoptosis 
that occurs within the villous trophoblast during PE [25] 
may have a link to the increased release of trophoblast-spe-
cific mRNA’s and the shedding of membrane particles into 
the maternal plasma [20]. PLAC1 mRNA concentrations are 
a function of PE severity and the time of onset. These con-
centrations are higher in early-onset PE than in late-onset 
PE [22, 26]. This is the first study in the literature evaluating 
maternal serum PLAC1 protein levels in early- and late-
-onset PE. We found that late-onset PE was associated with 
higher levels of maternal serum PLAC1 protein. Our findings 
also revealed that serum PLAC 1 levels were notably higher 
in pregnant women with late-onset PE when compared 
with those with early-onset. However, PLAC1 protein levels 
were not influenced from the severity of the disease in PE 
groups. The cellular function of PLAC1 remains unknown. 
However, it is believed to be associated with the membrane, 
and it was linked to trophoblast differentiation [7, 18]. It is 
also a possibility that the higher levels of PLAC1 are related 
to an abnormal interaction between trophoblast and uterine 
tissues which induces a defective vascular remodeling of 
maternal spiral arteries leading to a non-invasion of tropho-
blast and placental insufficiency [27, 28].
After all, our study has some limitations. As a potential 
effect of gestational age, the PLAC1 may manifest changes 
during pregnancy. More comprehensive studies are needed 
to reach a better conclusion and to provide percentile ranks 
for the pregnancy weeks.
In conclusion, the results established by our study 
showed that PLAC1 protein levels were significantly 
elevated in pregnant women with late-onset PE com-
pared with the healthy control group. Future studies are 
necessary to establish whether PLAC 1 protein levels may 
be used as a screening tool for late-onset PE.
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